Nanobiotix Announces Strategic Royalty Monetization Agreement with HealthCare Royalty

Nanobiotix S.A., a late-stage clinical biotechnology company, has entered into a royalty-based financing agreement with HealthCare Royalty (HCRx) for up to $71 million. This non-dilutive capital will extend Nanobiotix's cash runway into early 2028, supporting the company's development beyond key milestones in head and neck cancer and lung cancer. The agreement includes an upfront payment of $50 million and an additional $21 million contingent on certain conditions. HCRx will receive a capped portion of milestones and royalties on sales of JNJ-1900 (NBTXR3), a novel oncology product. The financing aims to establish a financial foundation for self-sustainability and the advancement of next-wave nanotherapeutic platforms. The agreement also involves a royalty-only tail period and repayment obligations through a French law trust. TD Cowen acted as the sole financial advisor to Nanobiotix.